Search research articles
Contact Us
Filters
Showing results (1-10 of 493) with videos related to
Page
of 50
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2006
Cytokine-based therapy and biochemotherapy for advanced melanoma
Michael B Atkins
Medical Oncology (Northwood, London, England)
|
January 24, 2009
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy
Michael B Atkins
Hematology/Oncology Clinics of North America
|
October 6, 1998
Immunotherapy and experimental approaches for metastatic melanoma
M B Atkins
Seminars in Oncology
|
June 18, 2002
Interleukin-2: clinical applications
Michael B Atkins
Current Opinion in Oncology
|
March 1, 1997
The treatment of metastatic melanoma with chemotherapy and biologics
M B Atkins
International Journal of Antimicrobial Agents
|
October 21, 1999
Fusidic acid in bone and joint infections
B Atkins, T Gottlieb
Sports Medicine (Auckland, N.Z.)
|
March 30, 2000
Infectious diseases in rugby players: incidence, treatment and prevention
A Stacey, B Atkins
The Lancet. Oncology
|
February 2, 2013
Which drug, and when, for patients with BRAF-mutant melanoma?
Sekwon Jang, Michael B Atkins
British Medical Journal
|
November 23, 1974
Communications between general practitioners and consultants
A Long, J B Atkins
Clinical Pharmacology and Therapeutics
|
October 2, 2013
Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies
S Jang, M B Atkins
Page
of 50
Search research articles
Search
Showing results (1-10 of 493) with videos related to
Sort By:
Page
of 50
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2006
Cytokine-based therapy and biochemotherapy for advanced melanoma
Michael B Atkins
Medical Oncology (Northwood, London, England)
|
January 24, 2009
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy
Michael B Atkins
Hematology/Oncology Clinics of North America
|
October 6, 1998
Immunotherapy and experimental approaches for metastatic melanoma
M B Atkins
Seminars in Oncology
|
June 18, 2002
Interleukin-2: clinical applications
Michael B Atkins
Current Opinion in Oncology
|
March 1, 1997
The treatment of metastatic melanoma with chemotherapy and biologics
M B Atkins
International Journal of Antimicrobial Agents
|
October 21, 1999
Fusidic acid in bone and joint infections
B Atkins, T Gottlieb
Sports Medicine (Auckland, N.Z.)
|
March 30, 2000
Infectious diseases in rugby players: incidence, treatment and prevention
A Stacey, B Atkins
The Lancet. Oncology
|
February 2, 2013
Which drug, and when, for patients with BRAF-mutant melanoma?
Sekwon Jang, Michael B Atkins
British Medical Journal
|
November 23, 1974
Communications between general practitioners and consultants
A Long, J B Atkins
Clinical Pharmacology and Therapeutics
|
October 2, 2013
Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies
S Jang, M B Atkins
Page
of 50